PFE
PFE
$28.74
+$0.07 (+0.24%)
About
No description available for this stock.
Price History (Last 30 Days)
Latest News & Updates
Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-...
Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.
Despite being down 35% year-to-date, Alnylam Pharmaceuticals has rebounded 25% s...
Despite being down 35% year-to-date, Alnylam Pharmaceuticals has rebounded 25% since late July and maintains strong analyst support with 18 of 21 analysts rating it as a buy or strong buy. The stock's attractive valuation (19.7x forward earnings, 0.32 PEG ratio) and favorable market dynamics—including reduced competition from a failed rival drug and extended patent protection for Pfizer's competing therapy—support the bullish outlook. However, investors should monitor demand normalization for Amvuttra and potential developments from the failed Wainua trial.
Federal Reserve Chair Kevin Warsh's hawkish stance signals sustained higher inte...
Federal Reserve Chair Kevin Warsh's hawkish stance signals sustained higher interest rates to combat inflation. While this increases competition for dividend stocks from Treasury bonds, big pharma dividend stocks like Pfizer, AbbVie, and Bristol Myers Squibb should remain resilient due to strong fundamentals and manageable debt service costs. Historical data shows pharma-specific business factors matter more than interest rates for stock performance.
The article compares two early-stage quantum technology companies: D-Wave Quantu...
The article compares two early-stage quantum technology companies: D-Wave Quantum, which has commercial customers and $24.6M in revenue but is burning cash rapidly with a -1,444% net margin, and QuantumScape, a pre-revenue solid-state battery developer with a stronger cash cushion and clearer path to commercialization. The author recommends QuantumScape as the better speculative bet due to its financial runway, despite both being high-risk moonshot investments years from profitability.
The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD...
The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.
The global autoimmune disease therapeutics market is projected to grow from USD...
The global autoimmune disease therapeutics market is projected to grow from USD 133 billion in 2025 to USD 255 billion by 2034, with an 8% CAGR. Growth is driven by rising prevalence of autoimmune disorders, increasing adoption of biologics and targeted therapies, advancements in precision medicine, and expanding biosimilar availability. North America leads with 44% market share, while Asia-Pacific is the fastest-growing region. Key players include AbbVie, Johnson & Johnson, Pfizer, Novartis, and Roche.
Artificial intelligence is accelerating vaccine adjuvant discovery and optimizat...
Artificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.
The National Association of Specialty Pharmacy (NASP) recognized industry leader...
The National Association of Specialty Pharmacy (NASP) recognized industry leaders and organizations at its annual conference in National Harbor, Maryland. Award recipients included Optum Specialty Pharmacy (Specialty Pharmacy of the Year), Van Chau from UC Davis Health (Pharmacist of the Year), and Pfizer (Manufacturer of the Year), among others. The record-breaking conference attracted over 2,400 specialty pharmacy professionals.
The article compares two dividend investment strategies: Eli Lilly offers modest...
The article compares two dividend investment strategies: Eli Lilly offers modest 0.6% yield but exceptional 15.3% annual dividend growth rate and strong growth prospects in the GLP-1 market, while Pfizer provides a high 6.2% yield with sustainable dividends backed by $11 billion in free cash flow. The choice depends on investor priorities—Eli Lilly suits those seeking growth and future dividend increases, while Pfizer appeals to investors prioritizing immediate income.
A comprehensive market research report analyzing co-development deals in pharmac...
A comprehensive market research report analyzing co-development deals in pharmaceuticals and biotechnology from 2016-2026 has been released. The report covers deal structures, financial terms, the top 25 most active dealmakers, and provides access to actual SEC-filed contract documents. Co-development partnerships are highlighted as a strategic approach for companies to share R&D costs, risks, and commercial opportunities while accelerating product development timelines.
